We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+32.97%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$340M
AUM Growth
+$36.5M
Cap. Flow
-$17.9M
Cap. Flow %
-5.28%
Top 10 Hldgs %
87.03%
Holding
26
New
1
Increased
2
Reduced
2
Closed
3

Top Buys

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$5.69M
2
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$2.77M
3
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$966K

Top Sells

Rank Stock Value
1
ACRS icon
Aclaris Therapeutics
ACRS
+$12.3M
2
CLCD
CoLucid Pharmaceuticals, Inc.
CLCD
+$8.19M
3
RGNX icon
Regenxbio
RGNX
+$6.53M
4
OCRX
Ocera Therapeutics, Inc.
OCRX
+$322K
5
ZSAN
Zosano Pharma Corporation
ZSAN
+$77K

Sector Composition

Rank Sector Weight
1 Healthcare 93.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLCD
26
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
– –
-225,000
Closed -$8.19M
1
2

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.2B AUM 35.94% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.21B AUM 49% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM

Vivo Capital's Q1 2017 Portfolio in Review

As of Q1 2017, Vivo Capital held 26 positions worth $340M, up 12% from $303M the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Vivo Capital withdrew a net $17.9M in Q1 2017, closing 3 positions and reducing 2 holdings. Its most notable exit was CoLucid Pharmaceuticals, Inc., an estimated $8.19M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 92% a quarter earlier.

Against the trend, Vivo Capital opened a new position in Aurinia Pharmaceuticals worth $4.4M.

  • Vivo Capital's largest Q1 2017 buy was Aurinia Pharmaceuticals: 600,000 shares worth $4.4M.
  • Vivo Capital added most to Soleno Therapeutics in Q1 2017, an estimated $5.69M increase.
  • Vivo Capital's biggest Q1 2017 reduction was Aclaris Therapeutics, cutting an estimated $12.3M.
  • Vivo Capital fully exited CoLucid Pharmaceuticals, Inc. in Q1 2017, selling an estimated $8.19M.
  • Vivo Capital's ten largest holdings make up 87% of its $340M portfolio in Q1 2017.
  • Vivo Capital opened 1 new position and closed 3 in Q1 2017.
  • Vivo Capital's portfolio value rose 12% quarter-over-quarter to $340M.

Based on Vivo Capital's 13F filing for Q1 2017, filed 15 May 2017.